Tyra Biosciences
TYRA
77 hedge funds and large institutions have $768M invested in Tyra Biosciences in 2024 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 25 increasing their positions, 16 reducing their positions, and 7 closing their positions.
214% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 7
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
56% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 16
55% more capital invested
Capital invested by funds: $496M → $768M (+$273M)
24% more funds holding
Funds holding: 62 → 77 (+15)
6.09% more ownership
Funds ownership: 83.12% → 89.21% (+6.1%)
85% less call options, than puts
Call options by funds: $10K | Put options by funds: $67K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$52.2M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$31.5M |
| 3 |
NI
Nextech Invest
Zurich,
Switzerland
|
+$25.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.8M |
| 5 |
O
OrbiMed
New York
|
+$12.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$3.19M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.9M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$782K |
| 4 |
Morgan Stanley
New York
|
-$592K |
| 5 |
JP Morgan Chase
New York
|
-$346K |
TYRA Hedge Fund Activity: Q1 2024 in Review
77 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Tyra Biosciences (TYRA) for Q1 2024, worth a combined $768M — up 55% from $496M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new TYRA positions and 7 closed out — a net gain of 15 holders — while 25 added to existing stakes and 16 trimmed.
The largest buyer was RA Capital Management, adding an estimated $52.2M. The largest seller was Frazier Life Sciences Management, cutting an estimated $3.19M.
- 77 institutional investors held Tyra Biosciences (TYRA) as of Q1 2024, up from 62 in Q4 2023.
- Funds reported $768M of Tyra Biosciences stock for Q1 2024, up 55% quarter-over-quarter.
- 22 funds opened new Tyra Biosciences positions in Q1 2024 and 7 closed out, a net change of +15 holders.
- The largest Tyra Biosciences buyer in Q1 2024 was RA Capital Management, an estimated $52.2M added.
- The largest Tyra Biosciences seller in Q1 2024 was Frazier Life Sciences Management, an estimated $3.19M sold.
Based on aggregated 13F filings for Q1 2024.